$GUTS just announce the RS already...

$LONA is it just the realization that those warrants they were hoping for won't be exercised?? Or a leak maybe...

$LONA what is going on here?

Also wild, $BBC went down from +42% YTD to +17%, lost more than 50% of his YTD performance.

Took a glance at $BMEA on this dip. Decided to pass. Interesting mechanism of action but hepatotoxicity a problem. And with KURA having lunched the LLY-backed Caspian Therapeutics the situation gets even worse for BMEA. Let alone the cash raise before data...

$CUE why are they not going for higher dose >q12w dosing??

$BCYC has been too quite for a while now. I hope they are working on some deal.

$NVNO wtf... making it hard to stay invested with so many red flags... A generational opportunity per CEO but no insiders buying. Series of meaningless PRs and X posts And now a video series named "wtf"... Am I a fool for still believing that enVVe is actually very promising?

$LEGN Legend Biotech This biotech name has been on my watchlist for some time. They have just named the former Chief Commercial Officer for Novartis International – Ingrid Zhang – as their new CEO effectively immediately. Ingrid led Novartis’ China business and had held leadership positions at AstraZeneca and Pfizer. Core to Legend’s thesis is the commercial success of CARVYKTI – a CAR-T cell immunotherapy targeting BCMA (B-Cell Maturation Antigen) which is over-expressed in multiple myeloma, a type of blood cancer that forms in plasma cells. For patients with relapsed/refractory multiple myeloma, later-line indications can come in the form of CAR-T and/or bispecific TCE (T-Cell Engager) therapies. Doctors tend to reach for CAR-T first since it yields an optimal efficacy and safety profile. Also, the issue with bispecific is that they may result in gene mutations which can impair T cells when they are collected for CAR-T as a next-line indication. While TCEs have lower production costs and complexity – since they are pre-manufactured and does not require the process flow/interval of extraction, programming and infusion, CAR-T cell therapies such as CARVKYTI is a compelling option since it’s a one-time infusion (compared to TCEs which are typically administered over months or a year) with durable remissions and extended treatment-free intervals. After years of investments, Legend and J&J (their partner) have ramped enough production capacity to fully meet global demand, with product turnaround time kept within four weeks, manufacturing success rate of 99% and a 97% reliability rate – attesting to the yield and quality of their product. Also, Legend recently reached a major milestone, posting its first profitable quarter in 2Q 26 (on adjusted net income), which they expect to sustain through 2H 26. CARVYKTI stats & details: ■ 2Q 26 total net trade sales were at ~$657M (+50% y/y), with U.S. net trade sales growth at +32% and ex-U.S. sales growth at +128% ■ Availability has now reached 348 global sites across 19 global markets with the recent launch in Ireland ■ Peak sales target - for CARVYKTI alone- is estimated to be at least $5B (potentially up to $7B) per year. Underpinning this target is the population of relapsed or refractory myeloma patients in the U.S. (>100,000) and other major markets, with fewer than 10% having utilized a BCMA therapy, which presents a significant growth upside Now compare this to the stock’s current market cap of $3.4B As for their pipeline: 1) Autologous therapies ■ LB1908: for relapsed/refractory gastric & pancreatic cancers (met primary endpoint, patient follow-up) ■ LB2102 (targeting DLL-3): for second-line or later (2L+) small cell lung cancer and large cell neuroendocrine carcinoma (met primary endpoint, patient follow-up. Legend has a license agreement with Novartis to develop, manufacture and commercialize this/other potential CAR-T therapies targeting DLL-3 ■ LB2401/2402/2403 and LB2502: for relapsed/refractory multiple myeloma (patient follow-up / enrolling) 2) Allogeneic therapies ■ LB2404D/2405: for relapsed/refractory autoimmune diseases (enrolling) ■ LB2302/2303 and LB2406: for relapsed/refractory B-cell non-Hodgkin lymphoma (enrolling) 3) In vivo therapies ■ LB2501 (CD19 and CD20 dual targeting CAR-T): for relapsed/refractory B-cell non-Hodgkin lymphoma (enrolling) ■ LB2503/2505: for relapsed/refractory multiple myeloma (enrolling) Potential competition: ■ J&J’s Tecvayli + Talvey bispecific TCE ■ Gilead Sciences’ anito-cel, an investigational BCMA-targeted CAR T-cell therapy, which they acquired through the purchase of Arcellx earlier this year Legend’s arguments against competitive threats: ■ Their alliance with J&J remains robust. And the market growth for CAR-T and TCEs is not a zero-sum game given the large pool of patients in the U.S. and overseas with low penetration rates ■ Gilead/Arcell’s anito-cell is slated for a later-line indication (i.e. fourth-line treatment), compared to CARVYKTI (about 70% of CARVYKTI uses in the U.S. today are for second- to fourth-line patients)

$BIVI has an explanation and a spin for every failed trial... in all 3 indications (AD, PD, Long COVID). Long COVID data seem interesting to be honest but so many red flags in the PR

$BIVI always spins failed trials based on subgroup and/or post-hoc analyses...

$DFTX What a terrible AE. Nearly a third of patients were euphoric

$DFTX 100k patients seems like a pretty conservative estimation (in contrast to many biotechs claiming unreal peak sales) Am I missing sth?

$DFTX seems derisked from here

$KPTI close to 50% dilution. KPTI gets no cash for this. 50% dilution just to survive an extra month

$KPTI $20M worth of preferred shares convertible into common stock at $1.62 granted to lenders just to allow KPTI to survive until October... doesnt look good

$KPTI the next $SGMO?

$ALMS moving to ph3 based on benefit on high IFNGS subgroup? despite placebo vastly outperforming treatment in complementary subgroup? what am I missing here? Any biological reason why low-IFNGS subgroup would do better on placebo?

$BHVN What you need to know today: - the SK deal is not in danger. SK already knew about this when the deal was signed - Already enrolled patients stay in the trial. RISE3 trial completely unaffected. Topline in 2H as guided - New data within weeks will likely resolve the hold

$BHVN silly dip. Seems like a minor hold. Completed ph3 unaffected. Partner already knew about this when the deal was signed. Nth changes. Additional non-clinical data "in coming weeks".